Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MDM2 |
| Variant | C308Y |
| Impact List | missense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | MDM2 C308Y lies within the RanBP2-type zinc finger domain of the Mdm2 protein (UniProt.org). C308Y results in decreased Tp53 degradation (PMID: 17116689) and has been shown to confer MDM2 inhibitor resistance in cell culture (PMID: 23653682), and therefore, is predicted to lead to a loss of Mdm2 protein function. |
| Associated Drug Resistance | Y |
| Category Variants Paths |
MDM2 mutant MDM2 inact mut MDM2 C308Y |
| Transcript | NM_001367990.1 |
| gDNA | chr12:g.68839296G>A |
| cDNA | c.923G>A |
| Protein | p.C308Y |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_005268872.5 | chr12:g.68839296G>A | c.923G>A | p.C308Y | RefSeq | GRCh38/hg38 |
| XM_005268872 | chr12:g.68839296G>A | c.923G>A | p.C308Y | RefSeq | GRCh38/hg38 |
| NM_001367990.1 | chr12:g.68839296G>A | c.923G>A | p.C308Y | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 C308Y | Advanced Solid Tumor | predicted - resistant | Nutlin-3a | Preclinical - Biochemical | Actionable | In a preclinical study, MDM2 C308Y conferred moderate resistance to Nutlin-3a as demonstrated by decreased restoration of Tp53 activity in reporter assays in culture (PMID: 23653682). | 23653682 |